Mitomycin C in patients with gynecological malignancies.

Abstract

Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma. This review presents and discusses the current treatment options with MMC in patients with breast, cervical, and vulvar carcinomas, as well as rarer gynecological malignancies. New combinations and developments are also presented and their potential clinical relevance is examined. Consequently, also for the next years a MMC-containing chemotherapy continues to be a relevant part of an individualized therapy despite numerous innovative new drugs, especially for the salvage therapy of metastatic breast cancer and the simultaneous radiochemotherapy of other gynecological malignancies.

• Authors: Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav Strnad, Peter A Fasching, Michael P Lux
• Journal: Onkologie (Onkologie) Vol. 33 Issue 10 Pg. 547-57 ( 2010) ISSN: 1423-0240 [Electronic] Switzerland
• PMID: 20926904 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2010 S. Karger AG, Basel.

Chemical References

• Cytostatic Agents
• Mitomycin

Topics

• Breast Neoplasms (drug therapy)
• Cytostatic Agents (therapeutic use)
• Female
• Genital Neoplasms, Female (drug therapy)
• Humans
• Mitomycin (therapeutic use)
• Salvage Therapy (methods)